SCHEMBL24312280

SCHEMBL24312280

CN(C)CC#Cc1cc(Cl)cc(N2CCOCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 1/20 0.44
▸ KMT2A Q03164 3/20 0.41
▸ CYP1A2 P05177 3/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CNR2 P34972 1/20 0.40
▸ PIK3CB P42338 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ CRHBP P24387 1/20 0.38
▸ CRHR2 Q13324 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PIK3CA P42336 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312333 0.81 RAF1 (0.40) RAF1PIK3CB
SCHEMBL24312182 0.80 KMT2A (0.46) KMT2ACYP1A2CYP2D6MAPTMEN1
SCHEMBL29611284 0.80 MAPT (0.44) RAF1KMT2ACYP1A2CYP2D6MAPT
SCHEMBL24312249 0.80 MAPT (0.44) RAF1KMT2ACYP1A2CYP2D6MAPT
SCHEMBL24595190 0.79 MAPT (0.47) KMT2ACYP1A2CYP2D6MAPTMEN1
SCHEMBL29610649 0.76 MAPT (0.49) KMT2ACYP1A2CYP2D6MAPTMEN1
SCHEMBL24312193 0.76 MAPT (0.49) KMT2ACYP1A2CYP2D6MAPTMEN1
SCHEMBL24312231 0.75 KMT2A (0.44) KMT2ACYP1A2CYP2D6MAPTMEN1
SCHEMBL24312197 0.75 AKT1 (0.43) RAF1KMT2ACYP1A2CYP2D6MAPT
SCHEMBL17204101 0.74 MAPT (0.61) KMT2ACYP1A2CYP2D6MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-20220356160-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-11-10 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112170-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF RAF1 2/4885KMT2A 1631/4885CYP1A2 4302/4885
US-11746095-B2 Inhibtors of RAF kinases RAF1, BRAF, ARAF RAF1 1/4885KMT2A 2824/4885CYP1A2 4124/4885
US-20220356160-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF RAF1 2/4885KMT2A 1631/4885CYP1A2 4302/4885
US-11377431-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF RAF1 2/4885KMT2A 1631/4885CYP1A2 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback